Cooley Advises Neurocrine on $2.9 Billion Acquisition of Soleno Therapeutics

"Neurocrine Therapeutics agreed to acquire Soleno Therapeutics, a developer of rare-disease and endocrinology treatments, for $2.9 billion. Law firm Cooley advised Neurocrine on the deal, led by Jamie Leigh and Kevin Cooper with support from Ryan Genkin, Nicholaus Johnson, Katie Benvenuti, Nicholas Orr, Sunny Liu, Michelle Hunt, Vittoria Rainone, Joe Perry, Matthew Scarano and Sharon Davidov. Cooley has served as Neurocrine’s primary corporate and transactional counsel for about 20 years, advising on prior matters including the Diurnal acquisition (2023), a $517.5 million convertible note offering (2017), and numerous licensing agreements with major life‑sciences partners."